Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

RGD DISEASE ONTOLOGY - ANNOTATIONS

RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.

Term:visceral leishmaniasis
go back to main search page
Accession:DOID:9146 term browser browse the term
Definition:A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
Synonyms:exact_synonym: KALA-AZAR, SUSCEPTIBILITY TO, 1;   KALA-AZAR, SUSCEPTIBILITY TO, 2;   KALA-AZAR, SUSCEPTIBILITY TO, 3;   KAZA1;   KAZA2;   KAZA3;   Kala Azar;   black fever;   infection by visceral leishmaniasis;   visceral leishmaniasis, susceptibility to, 1;   visceral leishmaniasis, susceptibility to, 3
 primary_id: MESH:D007898
 alt_id: OMIM:608207;   OMIM:611381;   OMIM:611382;   RDO:0005977
 xref: ICD10CM:B55.0;   ICD9CM:085.0;   NCI:C34771;   OMIM:PS608207;   ORDO:507
For additional species annotation, visit the Alliance of Genome Resources.


show annotations for term's descendants           Sort by:
 
visceral leishmaniasis term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AICDA activation induced cytidine deaminase ISO mRNA:altered expression:Bcell,CD4Tcell RGD PMID:31001826 RGD:32716386 NCBI chr27:37,064,107...37,073,791
Ensembl chr27:37,064,080...37,073,789
JBrowse link
G CCL4 chemokine (C-C motif) ligand 4 ISO protein:increased expression:serum RGD PMID:21991751 RGD:5683905 NCBI chr 9:37,681,342...37,682,691
Ensembl chr 9:37,676,966...37,710,209
JBrowse link
G CCR2 C-C motif chemokine receptor 2 ISO RGD PMID:24818662 RGD:8661728 NCBI chr20:42,305,344...42,313,258
Ensembl chr20:42,307,580...42,308,698
JBrowse link
G CCR3 C-C motif chemokine receptor 3 ISO protein:increased expression:blood, T cell RGD PMID:15379987 RGD:6893393 NCBI chr20:42,382,380...42,398,449
Ensembl chr20:42,383,135...42,384,217
JBrowse link
G CCR5 C-C motif chemokine receptor 5 treatment ISO RGD PMID:24617012 RGD:14401738 NCBI chr20:42,293,288...42,297,952
Ensembl chr20:42,294,996...42,297,952
JBrowse link
G CD40 CD40 molecule treatment ISO RGD PMID:14573667 RGD:8547750 NCBI chr24:33,352,992...33,383,488
Ensembl chr24:33,372,930...33,383,301
JBrowse link
G CD40LG CD40 ligand ISO RGD PMID:14573667 RGD:8547750 NCBI chr  X:107,001,421...107,023,007
Ensembl chr  X:107,010,890...107,023,006
JBrowse link
G CRP C-reactive protein ISO CTD Direct Evidence: marker/mechanism CTD PMID:10467834 NCBI chr38:22,396,787...22,398,180
Ensembl chr38:22,396,263...22,399,166
JBrowse link
G CSF2 colony stimulating factor 2 treatment ISO CTD Direct Evidence: marker/mechanism RGD
CTD
PMID:8035028, PMID:17404324 RGD:10449527 NCBI chr11:20,342,880...20,346,959
Ensembl chr11:20,344,648...20,346,959
JBrowse link
G CXCL10 C-X-C motif chemokine ligand 10 ISO mRNA:increased expression:liver RGD PMID:16239557 RGD:27095947 NCBI chr32:598,406...599,925
Ensembl chr32:597,987...599,979
JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 ISO CTD Direct Evidence: marker/mechanism CTD PMID:22461696 NCBI chr13:62,435,035...62,438,354
Ensembl chr13:62,434,422...62,438,354
JBrowse link
G HLA-DRB1 MHC class II DLA DRB1 beta chain ISO CTD Direct Evidence: marker/mechanism CTD PMID:23291585 NCBI chr12:2,151,409...2,164,564 JBrowse link
G HMOX1 heme oxygenase 1 ISO CTD Direct Evidence: marker/mechanism CTD PMID:22461696 NCBI chr10:28,744,404...28,751,544
Ensembl chr10:28,743,795...28,751,773
JBrowse link
G IFNG interferon gamma treatment ISO CTD Direct Evidence: therapeutic RGD
CTD
PMID:1901333, PMID:3104456, PMID:7854095 RGD:8158041 NCBI chr10:10,406,866...10,411,698
Ensembl chr10:10,406,867...10,411,698
JBrowse link
G IL10 interleukin 10 ISO CTD Direct Evidence: marker/mechanism CTD
RGD
PMID:15716043, PMID:17404324, PMID:22461696, PMID:29745990 RGD:14975172 NCBI chr 7:5,933,285...5,937,057
Ensembl chr 7:5,933,285...5,937,057
JBrowse link
G IL10RA interleukin 10 receptor subunit alpha ISO CTD Direct Evidence: therapeutic CTD PMID:15716043 NCBI chr 5:15,675,775...15,688,935
Ensembl chr 5:15,677,547...15,682,163
JBrowse link
G IL18 interleukin 18 susceptibility ISO RGD PMID:16879623 RGD:8655922 NCBI chr 5:20,972,742...20,995,327
Ensembl chr 5:20,972,871...20,995,348
JBrowse link
G IL1B interleukin 1 beta ISO CTD Direct Evidence: marker/mechanism CTD PMID:17404324 NCBI chr17:37,019,329...37,033,388
Ensembl chr17:37,019,329...37,024,458
JBrowse link
G IL6 interleukin 6 ISO CTD Direct Evidence: marker/mechanism CTD PMID:7554475, PMID:17404324, PMID:22461696 NCBI chr14:36,474,268...36,478,519
Ensembl chr14:36,473,394...36,478,519
JBrowse link
G LTA lymphotoxin alpha severity ISO DNA:polymorphisms RGD PMID:12438370, PMID:15579454 RGD:8548784, RGD:8548789 NCBI chr12:1,070,608...1,073,053
Ensembl chr12:1,071,192...1,073,067
JBrowse link
G LTB lymphotoxin beta ISO RGD PMID:12115620 RGD:8548822 NCBI chr12:1,079,340...1,084,785
Ensembl chr12:1,079,358...1,081,153
JBrowse link
G MBL2 mannose binding lectin 2 disease_progression
susceptibility
ISO protein:increased expression:serum:
DNA:SNPs,haplotype:promoter,exon:
DNA:polymorphism:promoter:
RGD PMID:17357060, PMID:22995279, PMID:26297290 RGD:11522692, RGD:8693721, RGD:8693726 NCBI chr 4:29,419,886...29,424,377 JBrowse link
G MIR155 microRNA mir-155 ISO RGD PMID:31182615 RGD:21081525 NCBI chr31:21,078,768...21,078,828
Ensembl chr31:21,078,758...21,078,833
JBrowse link
G SLC11A1 solute carrier family 11 member 1 ISO CTD Direct Evidence: marker/mechanism RGD
CTD
PMID:16597321, PMID:17067929 RGD:5684944 NCBI chr37:25,039,203...25,047,461
Ensembl chr37:25,038,360...25,047,282
JBrowse link
G STAT4 signal transducer and activator of transcription 4 ISO RGD PMID:24242758 RGD:8661696 NCBI chr37:1,566,563...1,685,378
Ensembl chr37:1,566,585...1,829,894
JBrowse link
G TLR2 toll like receptor 2 disease_progression ISO RGD PMID:23589575 RGD:15090808 NCBI chr15:51,454,557...51,465,429
Ensembl chr15:51,454,695...51,465,241
JBrowse link
G TNF tumor necrosis factor severity ISO CTD Direct Evidence: marker/mechanism
DNA:polymorphisms
CTD
RGD
PMID:1901333, PMID:12438370, PMID:15579454, PMID:22461696 RGD:8548784, RGD:8548789 NCBI chr12:1,074,561...1,076,425
Ensembl chr12:1,074,552...1,076,425
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  disease 12699
    disease of anatomical entity 12239
      endocrine system disease 0
        liver disease 2243
          visceral leishmaniasis 27
Path 2
Term Annotations click to browse term
  disease 12699
    disease of anatomical entity 12239
      nervous system disease 10001
        sensory system disease 4836
          skin disease 2530
            Infectious Skin Diseases 159
              Parasitic Skin Diseases 54
                leishmaniasis 52
                  visceral leishmaniasis 27
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.